Michael A Mcghee, MD | |
2305 Springhill Rd, Suite 8, Bryant, AR 72019-7552 | |
(501) 943-3214 | |
(501) 943-3219 |
Full Name | Michael A Mcghee |
---|---|
Gender | Male |
Speciality | Otolaryngology |
Experience | 31 Years |
Location | 2305 Springhill Rd, Bryant, Arkansas |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1124001953 | NPI | - | NPPES |
040013831 | Other | AR | RAILROAD MEDICARE |
134132001 | Medicaid | AR |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Y00000X | Otolaryngology | C8454 (Arkansas) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Saline Memorial Hospital | Benton, AR | Hospital |
Baptist Health Medical Center-little Rock | Little rock, AR | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Arkansas Otolaryngology Center Pa | 9234113853 | 26 |
News Archive
A team of researchers at the Genetics Institute, University College London, tested whether any homoplasies observed in SARS-Cov-2 to date are significantly linked to increased viral transmission.
A research paper published in the American Journal of Infection Control says a systematic approach to preparing patients for surgery can reduce both secondary, hospital-acquired patient infections and related healthcare expenses nationwide.
The CSU educates thousands of public health professionals who work to improve the health of California's communities by promoting healthy lifestyles, preventing disease and removing environmental dangers.
PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat patients with acute infectious diseases and cardiovascular disorders, announced today that several of its defensin-mimetic antibiotic compounds have shown antimicrobial efficacy in an animal model against the bacteria that causes anthrax.
› Verified 2 days ago
Entity Name | Arkansas Otolaryngology Center Pa |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1164449500 PECOS PAC ID: 9234113853 Enrollment ID: O20040614000312 |
News Archive
A team of researchers at the Genetics Institute, University College London, tested whether any homoplasies observed in SARS-Cov-2 to date are significantly linked to increased viral transmission.
A research paper published in the American Journal of Infection Control says a systematic approach to preparing patients for surgery can reduce both secondary, hospital-acquired patient infections and related healthcare expenses nationwide.
The CSU educates thousands of public health professionals who work to improve the health of California's communities by promoting healthy lifestyles, preventing disease and removing environmental dangers.
PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat patients with acute infectious diseases and cardiovascular disorders, announced today that several of its defensin-mimetic antibiotic compounds have shown antimicrobial efficacy in an animal model against the bacteria that causes anthrax.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
Michael A Mcghee, MD 10201 Kanis Rd, Little Rock, AR 72205-6203 Ph: (501) 227-5050 | Michael A Mcghee, MD 2305 Springhill Rd, Suite 8, Bryant, AR 72019-7552 Ph: (501) 943-3214 |
News Archive
A team of researchers at the Genetics Institute, University College London, tested whether any homoplasies observed in SARS-Cov-2 to date are significantly linked to increased viral transmission.
A research paper published in the American Journal of Infection Control says a systematic approach to preparing patients for surgery can reduce both secondary, hospital-acquired patient infections and related healthcare expenses nationwide.
The CSU educates thousands of public health professionals who work to improve the health of California's communities by promoting healthy lifestyles, preventing disease and removing environmental dangers.
PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat patients with acute infectious diseases and cardiovascular disorders, announced today that several of its defensin-mimetic antibiotic compounds have shown antimicrobial efficacy in an animal model against the bacteria that causes anthrax.
› Verified 2 days ago